rhIL-15: Clinical Trials

5 trials of rhIL-15, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Recruiting 1, Terminated 1

Follow rhIL-15: new trials by email Literature Review of rhIL-15 trials Research Report on rhIL-15

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
rhIL-15, Dinituximab, Temozolomide - Neuroblastoma
Phase 1RecruitingNational Cancer Institute (NCI)402025-10-212026-10-21
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
rhIL-15, Obinutuzumab - Leukemia, Lymphocytic
Phase 1TerminatedNational Cancer Institute (NCI)12019-07-112022-03-22
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
rhIL-15, Avelumab - Peripheral T-cell Lymphoma NOS, Mycosis Fungoides
Phase 1CompletedNational Cancer Institute (NCI)82019-06-072022-09-13
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
rhIL-15, Ipilimumab, Nivolumab - Metastatic Solid Tumors, Treatment-Refractory Cancers
Phase 1CompletedNational Cancer Institute (NCI)312018-02-052025-12-18
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15 - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Phase 1CompletedNational Cancer Institute (NCI)202013-02-152017-09-15

Conditions studied

Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Leukemia (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Melanoma (1)  ·  Mycosis Fungoides (1)  ·  Neuroblastoma (1)  ·  Sezary Syndrome (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

National Cancer Institute (NCI) (5)

Countries

United States (5)

Top investigators

Kevin C Conlon, M.D. (2)  ·  Hong Ha Rosa Nguyen, M.D. (1)  ·  Jeffrey Miller (1)  ·  Jibran Ahmed, M.D. (1)

Results publications

PMID 32508818, PMID 33883258, PMID 29203590, PMID 30045932

NIH funding

U01CA154967 (1)